Atara Biotherapeutics, Inc. (NASDAQ:ATRA) Given Average Rating of "Hold" by Analysts
Atara Biotherapeutics, Inc. (NASDAQ:ATRA) Given Average Rating of "Hold" by Analysts
Shares of Atara Biotherapeutics, Inc. (NASDAQ:ATRA – Get Rating) have received a consensus rating of "Hold" from the eight research firms that are covering the stock, MarketBeat reports. Two analysts have rated the stock with a sell recommendation, three have issued a hold recommendation and two have assigned a buy recommendation to the company. The average 12-month target price among brokerages that have issued ratings on the stock in the last year is $18.71.
據MarketBeat報道,Atara BioTreateutics,Inc.(納斯達克代碼:ATRA-GET Rating)的股票已獲得覆蓋該股票的八家研究公司的共識評級為持有。兩名分析師對該股的評級為賣出建議,三名分析師給出了持有建議,兩名分析師對該公司提出了買入建議。在過去一年對該股進行評級的券商中,12個月目標價的平均水平為18.71美元。
ATRA has been the topic of a number of recent research reports. The Goldman Sachs Group dropped their price objective on Atara Biotherapeutics from $4.00 to $3.00 and set a "sell" rating on the stock in a report on Tuesday, August 9th. Mizuho decreased their price objective on Atara Biotherapeutics from $39.00 to $31.00 and set a "buy" rating on the stock in a report on Tuesday, August 16th. Finally, StockNews.com started coverage on Atara Biotherapeutics in a report on Wednesday, October 12th. They set a "hold" rating on the stock.
全反式維甲酸是最近一些研究報告的主題。在8月9日星期二的一份報告中,高盛夫婦將Atara BioTreateutics的目標價從4.00美元下調至3.00美元,並對該股設定了“賣出”評級。瑞穗將Atara BioTreateutics的目標價從39.00美元下調至31.00美元,並在8月16日(星期二)的一份報告中對該股設定了“買入”評級。最後,StockNews.com在10月12日星期三的一份報告中開始報道Atara BioTreateutics。他們對該股設定了“持有”評級。
Atara Biotherapeutics Stock Performance
Atara BioTreatetics股票表現
ATRA stock opened at $4.65 on Tuesday. The company has a market capitalization of $441.19 million, a price-to-earnings ratio of -1.88 and a beta of 1.00. Atara Biotherapeutics has a fifty-two week low of $2.83 and a fifty-two week high of $18.31. The stock has a fifty day moving average of $4.30 and a 200-day moving average of $4.74.
ATRA股票週二開盤報4.65美元。該公司市值為4.411億美元,市盈率為-1.88倍,貝塔係數為1.00。Atara BioTreateutics的股價為2.83美元,為52周低點,52周高點為18.31美元。該股的50日移動均線切入位為4.30美元,200日移動均線切入位為4.74美元。
Insider Transactions at Atara Biotherapeutics
Atara BioTreateutics的內幕交易
Institutional Trading of Atara Biotherapeutics
Atara生物療法的機構交易
Several hedge funds have recently bought and sold shares of ATRA. Envestnet Asset Management Inc. bought a new stake in Atara Biotherapeutics during the first quarter valued at about $112,000. New York State Common Retirement Fund boosted its stake in shares of Atara Biotherapeutics by 11.5% in the first quarter. New York State Common Retirement Fund now owns 64,445 shares of the biotechnology company's stock worth $599,000 after acquiring an additional 6,664 shares during the period. Qube Research & Technologies Ltd bought a new position in shares of Atara Biotherapeutics in the first quarter worth about $220,000. Teacher Retirement System of Texas boosted its stake in shares of Atara Biotherapeutics by 12.6% in the first quarter. Teacher Retirement System of Texas now owns 15,447 shares of the biotechnology company's stock worth $144,000 after acquiring an additional 1,728 shares during the period. Finally, Swiss National Bank boosted its stake in shares of Atara Biotherapeutics by 12.5% in the first quarter. Swiss National Bank now owns 177,700 shares of the biotechnology company's stock worth $1,651,000 after acquiring an additional 19,800 shares during the period.
幾家對衝基金最近買賣了ATRA的股票。Envestnet Asset Management Inc.在第一季度購買了Atara BioTreateutics的新股份,價值約為11.2萬美元。紐約州共同退休基金在第一季度將其在Atara BioTreateutics的股份增加了11.5%。紐約州共同退休基金現在擁有這家生物技術公司64,445股股票,價值599,000美元,在此期間又購買了6,664股。Qube Research&Technologies Ltd在第一季度購買了Atara BioTreateutics的新頭寸,價值約22萬美元。德克薩斯州教師退休系統在第一季度將其在Atara BioTreateutics的股份增加了12.6%。德克薩斯州教師退休系統在此期間額外購買了1,728股,現在擁有15,447股這家生物技術公司的股票,價值14.4萬美元。最後,瑞士國家銀行在第一季度增持了Atara BioTreateutics的股份12.5%。瑞士國家銀行目前持有這家生物技術公司177,700股股票,價值1,651,000美元,在此期間又購買了19,800股。
About Atara Biotherapeutics
Atara生物療法公司簡介
(Get Rating)
(獲取評級)
Atara Biotherapeutics, Inc is an allogeneic T-cell immunotherapy company, which pioneers the development of transformative therapies for patients with serious diseases including solid tumors, hematologic cancers, and autoimmune diseases. also delivers off-the-shelf treatments to patients with high unmet medical need.
Atara BioTreateutics,Inc.是一家同種異體T細胞免疫療法公司,該公司率先為包括實體瘤、血液病和自身免疫性疾病在內的嚴重疾病患者開發變革性療法。還為高度未得到滿足的醫療需求的患者提供現成的治療。
Read More
閲讀更多內容
- Get a free copy of the StockNews.com research report on Atara Biotherapeutics (ATRA)
- CrowdStrike Selloff: It's Time For Investors to Strike
- Pure Storage is a Steady Eddie Growing Storage Play
- Tesla Shares Are Sliding, Here's Why
- Insiders And Institutions Buy Fastenal, An Aristocrat To Be
- Is Big Lots the Next Bed Bath & Beyond Disaster in the Making?
- 免費獲取StockNews.com關於Atara生物療法(ATRA)的研究報告
- CrowdStrike拋售:投資者罷工的時候到了
- Pure Storage是穩步增長的存儲業務
- 特斯拉股價下滑,原因如下
- 內部人士和機構收購Fastenal,成為未來的貴族
- 大地塊是不是正在醖釀中的下一個牀上沐浴和超越災難?
Receive News & Ratings for Atara Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atara Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
獲得Atara生物療法日報的新聞和評級-在下面輸入您的電子郵件地址,通過MarketBeat.com的免費每日電子郵件時事通訊接收對Atara BioTreateutics和相關公司的最新新聞和分析師評級的每日簡要摘要。